Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1/2a open-label multiple ascending dose study of intrathecal VO659 in SCA1, SCA3, and Huntington's disease
2024-514328-18-00Phase 2Authorised
- Sponsor
- Vico Therapeutics
- Start
- Dec 2022
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 6
01
Overview
Phase 2, open-label, single-arm trial of VO659 in spinocerebellar ataxia type 1 (SCA1), machado-joseph disease (MJD) and Huntington disease (HD), sponsored by Vico Therapeutics. Primary endpoints: Treatment-related adverse events and dose relationship, Clinical safety parameters and 2 more. Planned start Dec 2022; status: authorised.
02
Drugs
VO659
03
Conditions
spinocerebellar ataxia type 1 (SCA1)machado-joseph disease (MJD)Huntington disease (HD)
Beyond the preview
Go deeper on 2024-514328-18-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514328-18-00.